IL-17 is a Potential Therapeutic Target in a Rodent Model of Otitis Media with Effusion

被引:9
|
作者
Zhang, Nanfeng [1 ]
Qian, Tingting [2 ,3 ]
Sun, Shan [2 ,3 ]
Caol, Wei [1 ]
Wang, Zhixian [1 ]
Liu, Danling [2 ,3 ]
Lie, Peifan [2 ,3 ]
Wu, Jingfang [2 ,3 ]
Li, Huawei [1 ,2 ,3 ]
Yang, Jianming [1 ]
机构
[1] Anhui Med Univ, Affiliated Hosp 2, Dept ENT, Hefei 230031, Anhui, Peoples R China
[2] Fudan Univ, Eye & ENT Hosp, Dept ENT Inst, Shanghai 200032, Peoples R China
[3] Fudan Univ, Eye & ENT Hosp, Otorhinolaryngol, State Key Lab Med Neurobiol,NHC Key Lab Hearing M, Shanghai 200032, Peoples R China
基金
中国国家自然科学基金;
关键词
otitis media with effusion; IL-17; anti-IL-17A monoclonal antibody; notch; RISK-FACTORS; CHILDREN; BALANCE; MECHANISMS; CYTOKINES; IMMUNITY; RECEPTOR; ALLERGY;
D O I
10.2147/JIR.S338598
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Otitis media with effusion (OME) is a non-suppurative inflammation of the middle ear that is characterized by middle ear effusion and hearing loss. However, the mechanisms of OME are not fully understood. The aim of this study was to determine the function and the mechanism of the IL-17 cytokine in the pathogenesis of OME and to investigate IL-17 as a potential strategy for the treatment of OME. Methods: In this study, the OME rat model was induced by ovalbumin (OVA) as previously described. The severity of OME was determined with an oto-endoscope, by histochemical analysis, and by acoustic immittance. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of RNA-sequencing (RNA-seq) data was carried out to analyze the signaling pathways related to the pathogenesis of OME, which indicated that IL-17 is involved in OME. The anti-IL-17A monoclonal antibody was administrated by nasal drip to block IL-17 to treat OME in the rat model. The rats were finally injected intraperitoneally with the inhibitor of Notch signaling pathway to study the mechanisms of IL-17-induced inflammation. Serum and lavage fluid were collected for the detection of related cytokines, and middle ear tissue was collected for Western blot, quantitative real-time PCR (qRT-PCR), and immunohisto-chemical and immunofluorescence analysis. Results: KEGG analysis of RNA-seq data suggested that the IL-17 signaling pathway might be involved in the onset of OME. IL-17 expression was confirmed to be increased in both the serum and the middle ear of the rat model. The monoclonal antibody against IL-17 neutralized IL-17, inhibited the inflammation in the middle ear, and reduced the overall severity of OME in vivo. Furthermore, the Notch signaling pathway was activated upon IL-17 upregulation in OME and was suppressed by IL-17 blockage. However, there was no change in IL-17 expression after Notch inhibitor treatment, which reduced the severity of OME in the rat middle ear. Conclusion: IL-17 plays a key role in the pathogenesis of the OVA-induced OME rat model. IL-17 induced inflammatory responses via the Notch signaling pathway and targeting IL-17 might be an effective approach for OME therapy.
引用
收藏
页码:635 / 648
页数:14
相关论文
共 50 条
  • [1] IL-17: a potential therapeutic target for rheumatoid arthritis?
    Qiang Xie
    Shi-Cun Wang
    Jun Li
    [J]. Clinical Rheumatology, 2012, 31 : 1145 - 1146
  • [2] IL-17: a potential therapeutic target for rheumatoid arthritis?
    Xie, Qiang
    Wang, Shi-Cun
    Li, Jun
    [J]. CLINICAL RHEUMATOLOGY, 2012, 31 (07) : 1145 - 1146
  • [3] Increased IL-17 and 22 mRNA expression in pediatric patients with otitis media with effusion
    Kwon, Oh Eun
    Park, Sang Hyun
    Kim, Sung Su
    Shim, Haeng Seon
    Kim, Min Gyeong
    Kim, Young Il
    Kim, Sang Hoon
    Yeo, Seung Geun
    [J]. INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY, 2016, 90 : 188 - 192
  • [4] IL-17, a potential therapeutic target for Sjogren's syndrome?
    Liu, Shan-Shan
    Ding, Ye
    Lou, Ji-Quan
    [J]. CLINICAL RHEUMATOLOGY, 2015, 34 (09) : 1657 - 1658
  • [5] IL-17, a potential therapeutic target for Sjögren’s syndrome?
    Shan-Shan Liu
    Ye Ding
    Ji-Quan Lou
    [J]. Clinical Rheumatology, 2015, 34 : 1657 - 1658
  • [6] Therapeutic potential of targeting IL-17
    Sarah A Jones
    Caroline E Sutton
    Daniel Cua
    Kingston H G Mills
    [J]. Nature Immunology, 2012, 13 (11) : 1022 - 1025
  • [7] IL-17: A THERAPEUTIC TARGET IN CYSTIC FIBROSIS
    Hsu, D.
    Cronauer, C.
    Taylor, P. R.
    Chmiel, J.
    Pearlman, E.
    Bonfield, T. L.
    [J]. PEDIATRIC PULMONOLOGY, 2014, 49 : 251 - 252
  • [8] IL-17: A promising therapeutic target for atherosclerosis
    Fan, Zhixing
    Yang, Jian
    Yang, Chaojun
    Yang, Jun
    Guo, Xin
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 202 : 930 - 931
  • [9] The role of IL-17 in systemic lupus erythematosus and its potential as a therapeutic target
    Koga, Tomohiro
    Ichinose, Kunihiro
    Kawakami, Atsushi
    Tsokos, George C.
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2019, 15 (06) : 629 - 637
  • [10] IL-17, an important prognostic factor and potential therapeutic target for breast cancer?
    Bian, Geng
    Zhao, Wen-Ying
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2014, 44 (02) : 604 - 605